Upgrading on Per Protocol versus For Cause surveillance prostate biopsies: An opportunity to decreasing the burden of active surveillance
The Prostate · 2023
DOI: 10.1002/pros.24556 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift The Prostate, 2023. Verfasst von Michael Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Wayne State University, Detroit, Michigan, USA. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Blue Cross Blue Shield of Michigan Foundation.
Abstract (Originalsprache)
Background
Most prostate cancer (PC) active surveillance (AS) protocols recommend “Per Protocol” surveillance biopsy (PPSBx) every 1–3 years, even if clinical and imaging parameters remained stable. Herein, we compared the incidence of upgrading on biopsies that met criteria for “For Cause” surveillance biopsy (FCSBx) versus PPSBx.
Methods
We retrospectively reviewed men with GG1 PC on AS in the Michigan Urological Surgery Improvement Collaborative (MUSIC) registry. Surveillance prostate biopsies obtained 1 year after diagnosis were classified as either PPSBx or FCSBx. Biopsies were retrospectively deemed FCSBx if any of these criteria were met: PSA velocity > 0.75 ng/mL/year; rise in PSA > 3 ng from baseline; surveillance magnetic resonance imaging (MRI) (sMRI) with a PIRADS ≥ 4; change in DRE. Biopsies were classified PPSBx if none of these criteria were met. The primary outcome was upgrading to ≥GG2 or ≥GG3 on surveillance biopsy. The secondary objective was to assess for the association of reassuring (PIRADS ≤ 3) confirmatory or surveillance MRI findings and upgrading for patients undergoing PPSBx. Proportions were compared with the chi‐squared test.
Results
We identified 1773 men with GG1 PC in MUSIC who underwent a surveillance biopsy. Men meeting criteria for FCSBx had more upgrading to ≥GG2 (45%) and ≥GG3 (12%) compared with those meeting criteria for PPSBx (26% and 4.9%, respectively, p < 0.001 and p < 0.001). Men with a reassuring confirmatory or surveillance MRI undergoing PPSBx had less upgrading to ≥GG2 (17% and 17%, respectively) and ≥GG3 (2.9% and 1.8%, respectively) disease compared with men without an MRI (31% and 7.4%, respectively).
Conclusions
Patients undergoing PPSBx had significantly less upgrading compared with men undergoing FCSBx. Confirmatory and surveillance MRI seem to be valuable tools to stratify the intensity of surveillance biopsies for men on AS. These data may help inform the development of a risk‐stratified, data driven AS protocol.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Wayne State University, Detroit, Michigan, USA.
- University of Michigan Medical School, Ann Arbor, Michigan, USA.
- IHA Urology, St. Joseph Mercy Hospital, Ann Arbor, Michigan, USA.
- Department of Urology, Sparrow Point Hospitals, Lansing, Michigan, USA.
ORCID-Profile: Kevin B Ginsburg
Förderung
- Blue Cross Blue Shield of Michigan Foundation
Zitieren
APA
Wang, M., Lange, A., Perlman, D., Qi, J., George, A. K., Ferrante, S., Semerjian, A., Sarle, R., Cher, M. L., Ginsburg, K. B., & Michigan Urological Surgery Improvement Collaborative (2023). Upgrading on Per Protocol versus For Cause surveillance prostate biopsies: An opportunity to decreasing the burden of active surveillance. The Prostate. https://doi.org/10.1002/pros.24556
Vancouver
Wang M, Lange A, Perlman D, Qi J, George AK, Ferrante S, et al. Upgrading on Per Protocol versus For Cause surveillance prostate biopsies: An opportunity to decreasing the burden of active surveillance. The Prostate. 2023. doi:10.1002/pros.24556
BibTeX
@article{Wang2023,
author = {Wang, Michael and Lange, Andrew and Perlman, David and Qi, Ji and George, Arvin K and Ferrante, Stephanie and Semerjian, Alice and Sarle, Richard and Cher, Michael L and Ginsburg, Kevin B and Michigan Urological Surgery Improvement Collaborative, Michigan Urological Surgery Improvement Collaborative},
title = {Upgrading on Per Protocol versus For Cause surveillance prostate biopsies: An opportunity to decreasing the burden of active surveillance},
journal = {The Prostate},
year = {2023},
doi = {10.1002/pros.24556}
}
EUVIMED